{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:06:26Z","timestamp":1792688786650,"version":"4.5.0"},"reference-count":17,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007560","name":"Chiesi Farmaceutici","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007560","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2024,4,10]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Inhaled corticosteroid\/formoterol fumarate (ICS\/FF) as needed is recommended by the Global Initiative for Asthma (GINA) as sole therapy in adults with mild asthma, with low-dose maintenance ICS plus short-acting \u03b2<jats:sub>2<\/jats:sub>-agonist (SABA) as an alternative. SABA alone is no longer recommended. Given these changes in recommendations, the observational PRIME study aimed to describe real-world treatment patterns in mild asthma in Europe.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adults with asthma receiving low-dose maintenance ICS, or as needed ICS\/FF or SABA were followed for 6\u2005months. Data collected included Asthma Control Test (ACT), Asthma Control Questionnaire 5-item (ACQ-5), forced expiratory volume in 1\u2005s (FEV<jats:sub>1<\/jats:sub>) and asthma exacerbations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study was conducted in 883 patients in Germany, Italy, Poland and Spain; 833 (94.3%) completed follow-up. At enrolment, 32.2% received maintenance ICS, 56.3% ICS\/FF as needed and 11.6% SABA as needed; 57.4%, 61.2% and 54.9%, respectively, had well-controlled asthma (ACQ-5\/ACT definition). After 6\u2005months, changes in mean FEV<jats:sub>1<\/jats:sub>were small in the maintenance ICS and ICS\/FF as needed groups, whereas there was a decline in FEV<jats:sub>1<\/jats:sub>in the SABA as needed group. ACQ-5 total score improved from baseline in all three groups; 0.4%, 0.4% and 2.0% patients, respectively, had a severe exacerbation during the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>More patients received ICS\/FF as needed than SABA as needed, suggesting that physicians are aware of the latest treatment recommendations. This real-world study provides additional support to the use of ICS\/FF as needed as preferred treatment for patients with mild asthma, whereas SABA as needed was associated with a fall in lung function and more severe exacerbations.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00174-2024","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T15:45:23Z","timestamp":1714664723000},"page":"00174-2024","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world use of inhaled corticosteroid\/formoterol as needed in adults with mild asthma: the PRIME study"],"prefix":"10.1183","volume":"10","author":[{"given":"Guy","family":"Brusselle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5676-6126","authenticated-orcid":false,"given":"Peter","family":"Wark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glauco","family":"Cappellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Oosterom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Van Der Deijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Bucchioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Topole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2024101712243039000_10.5.00174-2024.1","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. 2018. Date last accessed: 9 February 2024. https:\/\/ginasthma.org\/archived-reports\/"},{"key":"2024101712243039000_10.5.00174-2024.2","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. 2019. Date last accessed: 9 February 2024. https:\/\/ginasthma.org\/archived-reports\/"},{"key":"2024101712243039000_10.5.00174-2024.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00047-2023"},{"key":"2024101712243039000_10.5.00174-2024.4","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. 2021. Date last accessed: 9 February 2024. https:\/\/ginasthma.org\/archived-reports\/"},{"key":"2024101712243039000_10.5.00174-2024.5","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. 2023. Date last accessed: 9 February 2024. https:\/\/ginasthma.org\/reports\/"},{"key":"2024101712243039000_10.5.00174-2024.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901963"},{"key":"2024101712243039000_10.5.00174-2024.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715274"},{"key":"2024101712243039000_10.5.00174-2024.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715275"},{"key":"2024101712243039000_10.5.00174-2024.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31948-8"},{"key":"2024101712243039000_10.5.00174-2024.10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/17476348.2023.2167714","article-title":"Is mild asthma truly mild? The patients\u2019 real-life setting","volume":"16","author":"Guarnieri","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"2024101712243039000_10.5.00174-2024.11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200801-060ST"},{"key":"2024101712243039000_10.5.00174-2024.12","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1164\/rccm.202304-0642ST","article-title":"Questions in mild asthma: an Official American Thoracic Society Research Statement","volume":"207","author":"Mohan","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2024101712243039000_10.5.00174-2024.13","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-216512"},{"key":"2024101712243039000_10.5.00174-2024.14","doi-asserted-by":"crossref","first-page":"100157","DOI":"10.1016\/j.jacig.2023.100157","article-title":"Effect of the COVID-19 pandemic on asthma exacerbations in New Zealand: an interrupted time series analysis","volume":"2","author":"Chan","year":"2023","journal-title":"J Allergy Clin Immunol Glob"},{"key":"2024101712243039000_10.5.00174-2024.15","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.3390\/diagnostics11091637","article-title":"Lung function decline in adult asthmatics: a 10-year follow-up retrospective and prospective study","volume":"11","author":"Bucchieri","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2024101712243039000_10.5.00174-2024.16","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/j.jaip.2023.03.053","article-title":"Is once versus twice daily dosing better for adherence in asthma and chronic obstructive pulmonary disease?","volume":"11","author":"De Keyser","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101712243039000_10.5.00174-2024.17","doi-asserted-by":"crossref","first-page":"e12210","DOI":"10.1002\/clt2.12210","article-title":"Measuring adherence to inhaled control medication in patients with asthma: comparison among an asthma app, patient self-report and physician assessment","volume":"13","author":"Cachim","year":"2023","journal-title":"Clin Transl Allergy"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00174-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:37:10Z","timestamp":1740375430000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00174-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,9,30]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1183\/23120541.00174-2024"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00174-2024","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,2]]}}}